Advocacy intelligence hub — real-time data for patient organizations
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
H. Lee Moffitt Cancer Center and Research Institute — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Amtagvi
Iovance Biotherapeutics, Inc.
Amtagvi
(lifileucel)Orphan drugacceleratedIovance Biotherapeutics, Inc.
12.1 Mechanism of Action The specific mechanism of action of AMTAGVI (lifileucel) is unknown.
Braftovi
(encorafenib)Orphan drugstandardArray BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.)
12.1 Mechanism of Action Encorafenib is a kinase inhibitor that targets BRAF V600E, as well as wild-type BRAF and CRAF in in vitro cell-free assays wi...
Opdualag
(nivolumab and relatlimab-rmbw)Orphan drugstandardBristol-Myers Squibb Company
Programmed Death Receptor-1 Blocking Antibody [EPC]
12.1 Mechanism of Action Relatlimab is a human IgG4 monoclonal antibody that binds to the LAG-3 receptor, blocks interaction with its ligands, includi...
Zelboraf
(VEMURAFENIB)Orphan drugstandardGenentech, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Vemurafenib is a low molecular weight, orally available inhibitor of some mutated forms of BRAF serine- threonine kinase, inc...
Alexander Shoushtari, MD, M.D
Memorial Sloan Kettering Cancer Center
📍 NEW YORK, NY
Marybeth Hughes, MD, MD
NCI - Surgery Branch
📍 NORFOLK, VA
Bita Esmaeli, MD, M.D
M.D. Anderson Cancer Center
📍 SPRING, TX
Amod Sarnaik, MD, M.D
Moffitt Cancer Center
📍 TAMPA, FL
Joshua Veatch, M.D., Ph.D
Fred Hutch/University of Washington Cancer Consortium
📍 SEATTLE, WA
Craig L. Slingluff, MD, M.D
University of Virginia
📍 CHARLOTTESVILLE, VA